We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 160

Product specificity requirement trumps patent construction for listing

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 5 2014

Lilly sought to list Canadian Patent No. 2,379,329 on the patent register for their product TRIFEXIS. The Minister refused, stating that the patent

Good news for antibody patent applications in Canada

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 27 2014

Patentees in the antibody arts in Canada have long been dogged by policy-based objections to claims that seek protection that is broader than the

Principles of comity should not override fairness

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 26 2014

Cobalt brought a motion pursuant to s. 6(5) of the NOC Regulations, to dismiss the proceeding as an abuse of process. The Court dismissed the motion

Patent invalid for lack of sound prediction of utility - Eli Lilly v. Novopharm

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • November 21 2011

This decision is the second by the Trial Judge in this matter

Rulings made to guide accountants in s. 8 damages reference

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • October 31 2012

This is the reference after the decision on the merits from the Trial and Court of Appeal in the s. 8 case

Patent Appeal Board finds no double patenting and that monoclonal antibody claims are sufficient when target polypeptide is described

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 25 2011

The application related to human receptors for the platelet factor 4 superfamily antibodies

Motion to set aside prohibition order because of impeachment action dismissed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 18 2011

In 2006, the Federal Court of Appeal allowed an appeal from a decision of the Federal Court and issued an Order of prohibition (prohibition Order) preventing the Minister of Health from issuing a Notice of Compliance until expiry of the patent

PMPRB requires generic company to report

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 11 2011

The main issue in this proceeding involved the definition of “patentee” as it pertains to the requirement to report to the Patented Medicines Prices Review Board (PMPRB). ratiopharm does not hold any patents

Amendments alleging contributory infringement not allowed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 4 2012

Nycomed appealed the decision of the Prothonotary, refusing to allow amendments to its Counterclaim that Apotex and Novopharm are liable for contributory infringement, and that they knew or ought to have known that their generic version would be used in an infringing manner

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 17 2013

Although the Court of Appeal had split 2-1, the Supreme Court refused Takeda's application for leave as well as the motion to intervene by Canada's